Ariana Pelosci

Erin Baurle, PsyD, discussed sleep-wake disturbances in patients with cancer and the efficacy of a CBT-I pilot program.

Persistent training and workflow gaps were listed as potential barriers of AYA care among oncologists.

In the non-HLA-A*02 arm of the FLAMINGO-1 trial, breast recurrence rates were less than 1% following treatment with GLSI-100.

The primary end point of PFS was met in the phase 3 FOURLIGHT-1 trial assessing atirmociclib plus fulvestrant in patients with HR+/HER2– breast cancer.

Gary L. Clayman, DMD, MD, FACS, discussed evaluating the link between GLP-1 receptor agonists and thyroid cancer.

Arms 7 and 8 of the BEGONIA trial showed comparable outcomes for patients with different PD-L1 expression when receiving dato-DXd/durvalumab for TNBC.

A total of 46.6% of patients showed a favorable response to ultrahypofractionation radiotherapy for locally advanced breast cancer.

A clinical clearance rate of 73% was noted among patients with basal cell carcinoma receiving 200 ug of doxorubicin microneedle array.

Sarah Poland, MD, discussed the landscape of immunotherapy in breast cancer, including clinical trial data, the rise of ADCs, and strategies for managing AEs.

A predetermined change control plan was authorized as part of the premarket approval, allowing for AI enhancements without the need for FDA oversight.

The EGFR/HER3 bispecific ADC met the primary end points of PFS and OS in patients with advanced triple-negative breast cancer.

Results from the BREAKWATER trial led to the traditional approval of encorafenib plus cetuximab and fluorouracil-based chemotherapy in BRAF-mutated CRC.

A novel agent in combination with olaparib has been granted fast track designation by the FDA for germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.

A Prescription Drug User Fee Act date of December 18, 2026, has been set for giredestrant plus everolimus in ER+, HER2–, ESR1-mutated breast cancer.

Fumiko Chino, MD, discussed the nuances of patient-centered care, addressing financial toxicity, AI bias in oncology, and survivorship.

Researchers analyzed postoperative complications and survival outcomes in patients with melanoma who underwent therapeutic lymph node dissection.

Since 2003, breast cancer has been one of the black box warnings associated with hormone replacement therapy for women experiencing menopause.

Julie M. Vose, MD, MBA, details insights from the Mantle Cell Lymphoma Scientific Consortium and Workshop, focusing on global clinical trial collaboration and sequencing BTK/BCL-2 inhibitors.

Sunil W. Dutta, MD, discussed hypofractionation in breast reconstruction and why clinical follow up remains a key "soft skill" in an AI-driven field.

Aminolevulinic acid plus red lamp therapy was given an sNDA by the FDA for the treatment of superficial basal cell carcinoma.

Emily Papai, MD, discussed her study on RECIST responses to neoadjuvant radiation in retroperitoneal sarcoma and the challenges of organ-sparing surgery.

Data from the KEYNOTE-B96 trial support the FDA approval of the pembrolizumab regimen in these gynecologic malignancies.

Deb Schrag, MD, MPH, discusses her journey into GI oncology, the development of patient-reported outcome systems, and her vision for the upcoming ASCO presidency.

OS and PFS rates were positive as demonstrated by real-world data in patients given SBRT for oligometastatic ovarian cancer.

Ifeoma Dikeocha, PhD, discussed how metabolic restriction and fasting-mimicking diets can help optimize chemotherapy outcomes in breast cancer.

Deb Schrag, MD, MPH, will assume the role as ASCO president in 2027, and hopes to continue the work of transcending global, political, and geographic barriers in oncology.

A PDUFA date in the second quarter of 2026 has been set for Dato-DXd in patients with unresectable or metastatic TNBC.

A biologics license application is planned to be sent to the FDA for OST-HER2 in recurrent, fully resected, pulmonary metastatic osteosarcoma.

IFx-2.0 showed a clinical benefit in an early phase 1 trial and has now been given orphan drug designation by the FDA for patients with stage IIB to IV cutaneous melanoma.

Results of 9 patients with metastatic breast cancer dosed with Bria-IMT have shown sustained survival.